White Paper
This whitepaper offers a high-level orientation around the key barriers to readiness and critical success factors for companies navigating the…
Blog
Now that the RACE for Children Act has come into effect, the drug development industry and patients and their families are optimistic—more drugs will…
Case Study
A Phase II, randomized, double-blind, placebo-controlled, 2-part study to evaluate the safety, tolerability, pharmacokinetics, clinical response, and…
Blog
PRA has partnered with The Leukemia and Lymphoma Society (LLS) on a global precision medicine clinical trial for children with relapsed acute…
Blog
Each August marks Children’s Eye Health and Safety Month, a time that brings eye injuries and vision loss to light. One out of 20 children ages three…
Fact Sheet
The NIH reports that 70% of medicines given to children have only been studied in adults; therefore, most drugs used to treat diseases in children…
Case Study
PRA’s project team turned around a challenging neonatal seizure study to enable successful recruitment. The relationships between the sponsor and the…
Blog
You may have heard the buzz surrounding a new severe inflammatory condition observed in children that seems to be connected with COVID-19 infection.…
Blog
In light of JIA Awareness Month, its treatments, its stigma, and more, we spoke with Dr. Johnny Peppers, Executive Director of Drug Development for…
White Paper
70% of medicines given to children have never been studied in pediatric populations. Children who need treatments represent a relatively small…